# US 2020/0138785 A1 · Use of gaboxadol, ganaxolone and allopregnanolone to treat movement disorders

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0138785 A1
- Document ID: US20200138785A1
- Status: Published application
- Kind: A1
- Application number: 16/674,601
- Filed: 2019-11-05
- Published: 2020-05-07
- Earliest claimed: 2018-11-05
- Applicants: Ovid Therapeutics Inc.
- Inventors: Matthew DURING
- Web page: https://patentgrep.com/patent/US20200138785A1

## CPC

- A61K 31/4162: condensed with heterocyclic ring systems
- A61K 31/437: the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A61K 31/57: substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K 31/573: substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
- A61P 25/14: for treating abnormal movements, e.g. chorea, dyskinesia
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Use of gaboxadol, allopregnanolone, or ganaxolone, or a pharmaceutical salt of any of the foregoing, for the treatment of cervical dystonia, multiple system atrophy, myoclonus, progressive supranuclear palsy, restless legs syndrome, Wilson's disease, ataxia, chorea, or dystonia in a subject in need thereof.

## Claims

### Claim 1

A method of treating a movement disorder selected from the group consisting of cervical dystonia, multiple system atrophy, myoclonus, progressive supranuclear palsy, restless legs syndrome, Wilson's disease, ataxia, chorea, and dystonia, comprising administering to a patient in need thereof about 0.05 mg to about 30 mg gaboxadol or a pharmaceutically acceptable salt thereof, wherein the method provides improvement in one or more symptoms of the cervical dystonia, multiple system atrophy, myoclonus, progressive supranuclear palsy, restless legs syndrome, Wilson's disease, ataxia, chorea, or dystonia in the patient.

### Claim 2 (depends on 1)

The method of claim 1, wherein the improvement is provided for more than 6 hours after administration.

### Claim 3 (depends on 1)

The method of claim 1, wherein the patient is administered a composition comprising about 1 mg to about 15 mg gaboxadol or a pharmaceutically acceptable salt thereof.

### Claim 4 (depends on 1)

The method of claim 1, wherein the in vivo plasma profile of the patient 6 hours after administration of the gaboxadol or pharmaceutically acceptable salt thereof is reduced by more than 50%.

### Claim 5 (depends on 1)

The method of claim 1, wherein the AUC6-12 of the patient 6 hours after administration of the gaboxadol or pharmaceutically acceptable salt thereof is less than 75% of the administered dose.

### Claim 6 (depends on 1)

The method of claim 1, wherein the composition provides improvement in the patient for more than 12 hours after the administering.

### Claim 7

A method of treating a movement disorder selected from the group consisting of cervical dystonia, multiple system atrophy, myoclonus, progressive supranuclear palsy, restless legs syndrome, Wilson's disease, ataxia, chorea, or dystonia, comprising administering to a patient in need thereof about 0.01 mg to about 20 mg allopregnanolone or a pharmaceutically acceptable salt thereof, wherein the method provides improvement in one or more symptoms of the cervical dystonia, multiple system atrophy, myoclonus, progressive supranuclear palsy, restless legs syndrome, Wilson's disease, ataxia, chorea, or dystonia in the patient.

### Claim 8 (depends on 7)

The method of claim 7, wherein the improvement is provided for more than 6 hours after administration.

### Claim 9 (depends on 7)

The method of claim 7, wherein the patient is administered a composition comprising about 1 mg to about 10 mg allopregnanolone or a pharmaceutically acceptable salt thereof.

### Claim 10 (depends on 7)

The method of claim 7, wherein the in vivo plasma profile of the patient 6 hours after administration of the allopregnanolone or pharmaceutically acceptable salt thereof is reduced by more than 50%.

### Claim 11 (depends on 7)

The method of claim 7, wherein the AUC6-12 of the patient 6 hours after administration of the allopregnanolone or pharmaceutically acceptable salt thereof is less than 75% of the administered dose.

### Claim 12 (depends on 7)

The method of claim 7, wherein the composition provides improvement in the patient for more than 12 hours after the administering.

### Claim 13

A method of treating a movement disorder selected from the group consisting of cervical dystonia, multiple system atrophy, myoclonus, progressive supranuclear palsy, restless legs syndrome, Wilson's disease, ataxia, chorea, or dystonia, comprising administering to a patient in need thereof about 5 mg to about 2000 mg ganaxolone or a pharmaceutically acceptable salt thereof, wherein the method provides improvement in one or more symptoms of the cervical dystonia, multiple system atrophy, myoclonus, progressive supranuclear palsy, restless legs syndrome, Wilson's disease, ataxia, chorea, or dystonia in the patient.

### Claim 14 (depends on 13)

The method of claim 13, wherein the improvement is provided for more than 6 hours after administration.

### Claim 15 (depends on 13)

The method of claim 13, wherein the patient is administered a composition comprising about 200 mg to about 1000 mg ganaxolone or a pharmaceutically acceptable salt thereof.

### Claim 16 (depends on 13)

The method of claim 13, wherein the in vivo plasma profile of the patient 6 hours after administration of the allopregnanolone or pharmaceutically acceptable salt thereof is reduced by more than 50%.

### Claim 17 (depends on 13)

The method of claim 13, wherein the AUC6-12 of the patient 6 hours after administration of the allopregnanolone or pharmaceutically acceptable salt thereof is less than 75% of the administered dose.

### Claim 18 (depends on 13)

The method of claim 13, wherein the composition provides improvement in the patient for more than 12 hours after the administering.

### Claim 19 (depends on 13)

The method of claim 13 wherein the patient is administered up to 1,800 mg of ganaxolone per day.

### Claim 20 (depends on 15)

The method of claim 15 wherein the composition comprises 200 mg or 400 mg ganaxolone.
